Related Experiment Videos
Antigen-specific agents in development
1Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Rockville, MD 20852, USA.
Abstract:
Differences in antigen expression between tumor cells and normal cells can be exploited to develop a variety of therapeutic anticancer agents. For example, vaccines containing tumor antigens can be administered to patients to elicit an immune-mediated attack against the tumor. Tumor antigens can also be targeted by passive transfer of monoclonal antibodies (MoAbs), or MoAbs that have been modified to carry toxin molecules. A large number of these antigen-specific agents are currently in clinical or late preclinical development. For the anticancer vaccines, much of the current development is focused on determining optimum immunization approaches. In the case of antibody-based reagents, second- and third-generation constructs are being developed to improve potency, decrease immunogenicity, and increase distribution to tumor.
Insights
Targeting tumor antigens with vaccines or monoclonal antibodies (MoAbs) offers promising anticancer therapies. Current research focuses on optimizing immunization strategies and developing advanced antibody constructs for improved efficacy.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Tumor antigens present unique targets for cancer therapy.
- Exploiting antigen differences between tumor and normal cells is a key strategy.
- Antigen-specific agents, including vaccines and monoclonal antibodies (MoAbs), are under development.
Purpose of the Study:
- To review the development of therapeutic anticancer agents targeting tumor antigens.
- To highlight current research directions in anticancer vaccines and antibody-based therapies.
Main Methods:
- Review of preclinical and clinical data on antigen-specific anticancer agents.
- Analysis of ongoing research in vaccine immunization approaches.
- Examination of advancements in monoclonal antibody (MoAb) construct development.
Main Results:
- Numerous antigen-specific agents are in late preclinical or clinical development.
- Anticancer vaccine research is focused on optimizing immunization methods.
- Second- and third-generation MoAbs are being developed to enhance potency and tumor distribution while reducing immunogenicity.
Conclusions:
- Targeting tumor antigens via vaccines and MoAbs represents a significant area of cancer therapeutic development.
- Ongoing research aims to refine these immunotherapeutic strategies for greater clinical success.